-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 11, CSPC Yuanda (Dalian) Pharmaceuticals submitted a 4-type generic listing application for rosuvastatin calcium tablets, which is expected to become the fourth lipid-lowering drug approved by CSPC
.
According to data from Minet.
com, in 2020, the total sales of rosuvastatin will exceed 4 billion yuan in terminals of public medical institutions in China and physical pharmacies in Chinese cities
.
Figure 1: The latest products declared by CSPC Source: CDE official website Figure 2: Overall sales of rosuvastatin in the past three years (unit: 100 million yuan) Source: Minet database Rosuvastatin is the first batch of domestically sourced (4+7 pilot, alliance expansion) catalog products, the overall sales volume in 2018 is close to 8 billion yuan
.
Affected by centralized procurement and the epidemic, the sales of rosuvastatin in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) in 2020 fell by 54.
19%.
The physical pharmacy terminal showed a continuous growth trend, and still ranked TOP2 in the ranking of blood lipid regulator market varieties
.
Figure 3: Current status of lipid-lowering drug products under CSPC Source: MID Drug Index Comprehensive Database of Minet.
Up to now, CSPC has 3 lipid-lowering drugs
.
In 2020, simvastatin and fenofibrate ranked TOP4 and TOP9 in the TOP20 common names of terminal blood lipid regulators in public medical institutions in China.
When the rosuvastatin reported for production this time is successfully approved, it will soon become the company's fourth It is a lipid-lowering drug, and at the same time, it has increased the product line of CSPC in the field of blood lipid regulators
.
It is reported that CSPC has previously acquired ezetimibe tablets, atorvastatin calcium tablets, levamlodipine maleate/atorvastatin calcium tablets, atorvastatin calcium dispersible tablets, atorvastatin calcium tablets, and atorvastatin calcium tablets.
The clinical approval of statin calcium soft capsules is expected to help the company deepen the market
.
.
According to data from Minet.
com, in 2020, the total sales of rosuvastatin will exceed 4 billion yuan in terminals of public medical institutions in China and physical pharmacies in Chinese cities
.
Figure 1: The latest products declared by CSPC Source: CDE official website Figure 2: Overall sales of rosuvastatin in the past three years (unit: 100 million yuan) Source: Minet database Rosuvastatin is the first batch of domestically sourced (4+7 pilot, alliance expansion) catalog products, the overall sales volume in 2018 is close to 8 billion yuan
.
Affected by centralized procurement and the epidemic, the sales of rosuvastatin in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) in 2020 fell by 54.
19%.
The physical pharmacy terminal showed a continuous growth trend, and still ranked TOP2 in the ranking of blood lipid regulator market varieties
.
Figure 3: Current status of lipid-lowering drug products under CSPC Source: MID Drug Index Comprehensive Database of Minet.
Up to now, CSPC has 3 lipid-lowering drugs
.
In 2020, simvastatin and fenofibrate ranked TOP4 and TOP9 in the TOP20 common names of terminal blood lipid regulators in public medical institutions in China.
When the rosuvastatin reported for production this time is successfully approved, it will soon become the company's fourth It is a lipid-lowering drug, and at the same time, it has increased the product line of CSPC in the field of blood lipid regulators
.
It is reported that CSPC has previously acquired ezetimibe tablets, atorvastatin calcium tablets, levamlodipine maleate/atorvastatin calcium tablets, atorvastatin calcium dispersible tablets, atorvastatin calcium tablets, and atorvastatin calcium tablets.
The clinical approval of statin calcium soft capsules is expected to help the company deepen the market
.
